Development of natural killer cells from hematopoietic stem cells

Molecules and Cells

Volumn 24, Issue 1, 2007, Pages 1-8

  Yoon, Suk Ran ^a   Chung, Jin Woong ^a   Choi, Inpyo ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Hematopoietic stem cells; Natural killer cell differentiation; NK cell therapy; NK receptor repertoire

Indexed keywords

CYTOKINE RECEPTOR; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TRANSCRIPTION FACTOR; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CD34 SELECTION; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL KILLING; CELL MATURATION; CELL THERAPY; CHROMOSOME 19; CLINICAL TRIAL; CYTOTOXICITY; DRUG MEGADOSE; GENETIC POLYMORPHISM; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL; HUMAN; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; MICROENVIRONMENT; NATURAL KILLER CELL; NONHUMAN; PHENOTYPE; RECEPTOR BINDING; SHORT SURVEY; TARGET CELL;

ADOPTIVE TRANSFER; ANIMALS; CELL DIFFERENTIATION; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELLS; HUMANS; KILLER CELLS, NATURAL; RECEPTORS, IMMUNOLOGIC;

EID: 35048854979     PISSN: 10168478     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (81)

1. Becknell, B. and Caligiuri, M. A. (2005) Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv. Immunol. 86, 209-239.
2. Biron, C. A. (1998) Role of early cytokines, including alpha and beta interferons (IFN-alpha/beta), in innate and adaptive immune responses to viral infections. Semin. Immunol. 10, 383-390.
3. Boggs, S. S., Trevisan, M., Patrene, K., and Geogopoulos, K. (1998) Lack of natural killer cell precursors in fetal liver of Ikaros knockout mutant mice. Nat. Immun. 16, 137-145.
4. Budagian, V., Bulanova, E., Paus, R., and Bulfone-Paus, S. (2006) IL-15/ IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev. 17, 259-280.
5. Carson, W. E., Giri, J. G., Lindemann, M. J., Linett, M. L., Ahdieh, M., et al. (1994) Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J. Exp. Med. 180, 1395-1403.
6. Colonna, M. (1997) Immunoglobulin superfamily inhibitory receptors: from natural killer cells to antigen-presenting cells. Res. Immunol. 148, 169-171.
7. Colonna, M. and Samaridis, J. (1995) Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science (New York, N. Y) 268, 405-408.
8. Cosman, D., Mullberg, J., Sutherland, C. L., Chin, W., Armitage, R., et al. (2001) ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14, 123-133.
9. Di Santo, J. P. (2006) Natural killer cell developmental pathways: a question of balance. Annu. Rev. Immunol. 24, 257-286.
10. Dorfman, J. R. and Raulet, D. H. (1998) Acquisition of Ly49 receptor expression by developing natural killer cells. J. Exp. Med. 187, 609-618.
11. Draghi, M., Yawata, N., Gleimer, M., Yawata, M., Valiante, N. M., et al. (2005) Single-cell analysis of the human NK cell response to missing self and its inhibition by HLA class I. Blood 105, 2028-2035.
12. Farag, S. S. and Caligiuri, M. A. (2004) Cytokine modulation of the innate immune system in the treatment of leukemia and lymphoma. Adv. Pharmacol. (San Diego, Calif) 51, 295-318.
13. Farag, S. S. and Caligiuri, M. A. (2006) Human natural killer cell development and biology. Blood Rev. 20, 123-137.
14. Farag, S. S., Fehniger, T. A., Ruggeri, L., Velardi, A., and Caligiuri, M. A. (2002) Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 100, 1935-1947.
15. Ferlazzo, G., Thomas, D., Lin, S. L., Goodman, K., Morandi, B., et al. (2004) The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J. Immunol. 172, 1455-1462.
16. Fernandez, N. C., Treiner, E., Vance, R. E., Jamieson, A. M., Lemieux, S., et al. (2005) A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 105, 4416-4423.
17. Freud, A. G. and Caligiur, M..A. (2006) Human natural killer cell development. Immunol. Rev. 214, 56-72.
18. Giebel, S., Locatelli, F., Lamparelli, T., Velardi, A., Davies, S., et al. (2003) Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 102, 814-819.
19. Hayashi, T., Hideshima, T., Akiyama, M., Podar, K., Yasui, H., et al. (2005) Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br. J. Haematol. 128, 192-203.
20. Held, W., Coudert, J. D., and Zimmer, J. (2003) The NK cell receptor repertoire: formation, adaptation and exploitation. Curr. Opin. Immunol. 15, 233-237.
21. Iizuka, K., Chaplin, D. D., Wang, Y., Wu, Q., Pegg, L. E., et al. (1999) Requirement for membrane lymphotoxin in natural killer cell development. Proc. Natl. Acad. Sci. USA 96, 6336-6340.
22. Ikawa, T., Fujimoto, S., Kawamoto, H., Katsura, Y., and Yokota, Y. (2001) Commitment to natural killer cells requires the helix-loop-helix inhibitor Id2. Proc. Natl. Acad. Sci. USA 98, 5164-5169.
23. Kather, A., Chantakru, S., He, H., Minhas, K., Foster, R., et al. (2003) Neither lymphotoxin alpha nor lymphotoxin beta receptor expression is required for biogenesis of lymphoid aggregates or differentiation of natural killer cells in the pregnant mouse uterus. Immunology 108, 338-345.
24. Kim, S., Poursine-Laurent, J., Truscott, S. M., Lybarger, L., Song, Y. J., et al. (2005) Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436, 709-713.
25. Klingemann, H. G. (2005) Natural killer cell-based immunotherapeutic strategies. Cytotherapy 7, 16-22.
26. Krause, S. W., Gastpar, R., Andreesen, R., Gross, C., Ullrich, H., et al. (2004) Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial. Clin. Cancer Res. 10, 3699-3707.
27. Lanier, L. L. (2001) Face off - the interplay between activating and inhibitory immune receptors. Curr. Opin. Immunol. 13, 326-331.
28. Lanier, L. L., Corliss, B. C., Wu, J., Leong, C., and Phillips, J. H. (1998) Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 391, 703-707.
29. Lee, K. N., Kang, H. S., Jeon, J. H., Kim, E. M., Yoon, S. R., et al. (2005) VDUP1 is required for the development of natural killer cells. Immunity 22, 195-208.
30. Lian, R. H., Chin, R. K., Nemeth, H. E., Libby, S. L., Fu, Y. X., et al. (2004) A role for lymphotoxin in the acquisition of Ly49 receptors during NK cell development. Eur. J. Immunol. 34, 2699-2707.
31. Lian, R. H. and Kumar, V. (2002) Murine natural killer cell progenitors and their requirements for development. Semin. Immunol. 14, 453-460.
32. Link, B. K., Ballas, Z. K., Weisdorf, D., Wooldridge, J. E., Bossler, A. D., et al. (2006) Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J. Immunother. (1997) 29, 558-568.
33. Ljunggren, H. G. and Karre, K. (1985) Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J. Exp. Med. 162, 1745-1759.
34. Ljunggren, H. G. and Karre, K. (1990) In search of the 'missing self': MHC molecules and NK cell recognition. Immunol. Today 11, 237-244.
35. Ljunggren, H. G. and Malmberg, K. J. (2007) Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 7, 329-339.
36. Ljunggren, H. G., Ohlen, C., Hoglund, P., Yamasaki, T., Klein, G., et al. (1988) Afferent and efferent cellular interactions in natural resistance directed against MHC class I deficient tumor grafts. J. Immunol. 140, 671-678.
37. Lohoff, M., Duncan, G. S., Ferrick, D., Mittrucker, H. W., Bischof, S., et al. (2000) Deficiency in the transcription factor interferon regulatory factor (IRF)-2 leads to severely compromised development of natural killer and T helper type 1 cells. J. Exp. Med. 192, 325-336.
38. Maki, G., Klingemann, H. G., Martinson, J. A., and Tam, Y. K. (2001) Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. J. Hematother. Stem Cell Res. 10, 369-383.
39. Makrigiannis, A. P., Pau, A. T., Schwartzberg, P. L., McVicar, D. W., Beck, T. W., et al. (2002) A BAC contig map of the Ly49 gene cluster in 129 mice reveals extensive differences in, gene content relative to C57BL/6 mice. Genomics 79, 437-444.
40. Miller, J. S., Cooley, S., Parham, P., Farag, S. S., Verneris, M. R., et al. (2007) Missing KIR-ligands is associated with less relapse and increased graft versus host disease (GVHD) followi,ng unrelated donor allogeneic HCT. Blood 109, 5058-5061.
41. Moretta, L. and Moretta, A. (2004) Killer immunoglobulin-like receptors. Curr. Opin. Immunol. 16, 626-633.
42. Moretta, A., Bottino, C., Sivori, S., Marcenaro, E., Castriconi, R., et al. (2001) Natural killer lymphocytes: "null cells" no more. Ital. J. Anat. Embryol. 106, 335-342.
43. Mrozek, E., Anderson, P., and Caligiuri, M. A. (1996) Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood 87, 2632-2640.
44. Ogasawara, K., Hida, S., Azimi, N., Tagaya, Y., Sato, T., et al. (1998) Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature 391, 700-703.
45. Passweg, J. R., Tichelli, A., Meyer-Monard, S., Heim, D., Stern, M., et al. (2004) Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 18, 1835-1838.
46. Petersson, M. G., Gronberg, A., Kiessling, R., and Ferm, M. T. (1995) Engagement of MHC class I proteins on natural killer cells inhibits their killing capacity. Scandinavian J. Immunol. 42, 34-38.
47. Raulet, D. H., Held, W., Correa, I., Dorfman, J. R., Wu, M. F., et al. (1997) Specificity, tolerance and developmental regulation of natural killer cells defined by expression of class I-specific Ly49 receptors. Immunol. Rev. 155, 41-52.
48. Raulet, D. H., Vance, R. E., and McMahon, C. W. (2001) Regulation of the natural killer cell receptor repertoire. Annu. Rev. Immunol. 19, 291-330.
49. Rosenberg, S. (1985) Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J. Natl. Cancer Inst. 75, 595-603.
50. Rosenberg, S. A. (2000) Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J. Sci. Am 6 (Suppl 1), S2-7.
51. Rosenberg, S. A., Lotze, M. T., Muul, L. M., Leitman, S., Chang, A. E., et al. (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 313, 1485-1492.
52. Rosmaraki, E. E., Douagi, I., Roth, C., Colucci, F., Cumano, A., et al. (2001) Identification of committed NK cell progenitors in adult murine bone marrow. Eur. J. Immunol. 31, 1900-1909.
53. Roth, C., Carlyle, J. R., Takizawa, H., and Raulet, D. H. (2000) Clonal acquisition of inhibitory Ly49 receptors on developing NK cells is successively restricted and regulated by stromal class I MHC. Immunity 13, 143-153.
54. Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., et al. (2002) Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science (New York, N.Y) 295, 2097-2100.
55. Ruggeri, L., Mancusi, A., Burchielli, E., Aversa, F., Martelli, M. F., et al. (2006) Natural killer cell alloreactivity and haplo-identical hematopoietic transplantation. Cytotherapy 8, 554-558.
56. Ruggeri, L., Mancusi, A., Perruccio, K., Burchielli, E., Martelli, M. F., et al. (2005) Natural killer cell alloreactivity for leukemia therapy. J. Immunother. (1997) 28, 175-182.
57. Ryan, J. C. and Seaman, W. E. (1997) Divergent functions of lectin-like receptors on NK cells. Immunol. Rev. 155, 79-89.
58. Saito, S., Nishikawa, K., Morii, T., Enomoto, M., Narita, N., et al. (1993) Cytokine production by CD16-CD56bright natural killer cells in the human early pregnancy decidua. Int. Immunol. 5, 559-563.
59. Samson, S. I., Richard, O., Tavian, M., Ranson, T., Vosshenrich, C. A., et al. (2003) GATA-3 promotes maturation, IFN-gamma production, and liver-specific homing of NK cells. Immunity 19, 701-711.
60. Shlomchik, W. D., Couzens, M. S., Tang, C. B., McNiff, J., Robert, M. E., et al. (1999) Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science (New York, N.Y) 285, 412-415.
61. Singh, H., Medina, K. L., and Pongubala, J. M. (2005) Contingent gene regulatory networks and B cell fate specification. Proc. Natl. Acad. Sci. USA 102, 4949-4953.
62. Smyth, M. J., Cretney, E., Kershaw, M. H., and Hayakawa, Y. (2004) Cytokines in cancer immunity and immunotherapy. Immunol. Rev. 202, 275-293.
63. Suck, G. (2006) Novel approaches using natural killer cells in cancer therapy. Semin. Cancer Biol. 16, 412-418.
64. Taki, S., Nakajima, S., Ichikawa, E., Saito, T., and Hida, S. (2005) IFN regulatory factor-2 deficiency revealed a novel checkpoint critical for the generation of peripheral NK cells. J. Immunol. 174, 6005-6012.
65. Tam, Y. K., Martinson, J. A., Doligosa, K., and Klingemann, H. G. (2003) Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy 5, 259-272.
66. Townsend, M. J., Weinmann, A. S., Matsuda, J. L., Salomon, R., Farnham, P. J., et al. (2004) T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. Immunity 20, 477-494.
67. Trowsdale, J., Barten, R., Haude, A., Stewart, C. A., Beck, S., et al. (2001) The genomic context of natural killer receptor extended gene families. Immunol. Rev. 181, 20-38.
68. Uhrberg, M., Parham, P., and Wernet, P. (2002) Definition of gene content for nine common group B haplotypes of the Caucasoid population: KIR haplotypes contain between seven and eleven KIR genes. Immunogenetics 54, 221-229.
69. Uhrberg, M., Valiante, N. M., Shum, B. P., Shilling, H. G., Lienert-Weidenbach, K., et al. (1997) Human diversity in killer cell inhibitory receptor genes. Immunity 7, 753-763.
70. Valiante, N. M., Uhrberg, M., Shilling, H. G., Lienert-Weidenbach, K., Arnett, K. L., et al. (1997) Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 7, 739-751.
71. van den Brink, M. R., Boggs, S. S., Herberman, R. B., and Hiserodt, J. C. (1990) The generation of natural killer (NK) cells from NK precursor cells in rat long-term bone marrow cultures. J. Exp. Med. 172, 303-313.
72. Vance, R. E., Kraft, J. R., Altman, J. D., Jensen, P. E., and Raulet, D. H. (1998) Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1(b). J. Exp. Med. 188, 1841-1848.
73. Vitale, M., Zimmer, J., Castriconi, R., Hanau, D., Donato, L., et al. (2002) Analysis of natural killer cells in TAP2-deficient patients: expression of functional triggering receptors and evidence for the existence of inhibitory receptor(s) that prevent lysis of normal autologous cells. Blood 99, 1723-1729.
74. Vosshenrich, C. A., Ranson, T., Samson, S. I., Corcuff, E., Colucci, F., et al. (2005) Roles for common cytokine receptor gamma-chain-dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo. J. Immunol. 174, 1213-1221.
75. Wagtmann, N., Rajagopalan, S., Winter, C. C., Peruzzi, M., and Long, E. O. (1995) Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer. Immunity 3, 801-809.
76. Warren, L. A. and Rothenberg, E. V. (2003) Regulatory coding of lymphoid lineage choice by hematopoietic transcription factors. Curr. Opin. Immunol. 15, 166-175.
77. Williams, N. S., Klem, J., Puzanov, I. J., Sivakumar, P. V., Bennett, M., et al. (1999) Differentiation of NK1.1+, Ly49+ NK cells from flt3+ multipotent marrow progenitor cells. J. Immunol. 163, 2648-2656.
78. Williams, N. S., Kubota, A., Bennett, M., Kumar, V., and Takei, F. (2000) Clonal analysis of NK cell development from bone marrow progenitors in vitro: orderly acquisition of receptor gene expression. Eur. J. Immunol. 30, 2074-2082.
79. Williams, N. S., Moore, T. A., Schatzle, J. D., Puzanov, I. J., Sivakumar, P. V., et al. (1997) Generation of lytic natural killer 1.1+, Ly-49- cells from multipotential murine bone marrow progenitors in a stroma-free culture: definition of cytokine requirements and developmental intermediates. J. Exp. Med. 186, 1609-1614.
80. Yokoyama, W. M. (1995) Natural killer cell receptors. Curr. Opin. Immunol. 7, 110-120.
81. Yokoyama, W. M. and Kim, S. (2006) Licensing of natural killer cells by self-major histocompatibility complex class I. Immunol. Rev. 214, 143-154.